KR102603897B1 - 흡입용 건조 분말 제형 - Google Patents

흡입용 건조 분말 제형 Download PDF

Info

Publication number
KR102603897B1
KR102603897B1 KR1020177005617A KR20177005617A KR102603897B1 KR 102603897 B1 KR102603897 B1 KR 102603897B1 KR 1020177005617 A KR1020177005617 A KR 1020177005617A KR 20177005617 A KR20177005617 A KR 20177005617A KR 102603897 B1 KR102603897 B1 KR 102603897B1
Authority
KR
South Korea
Prior art keywords
particles
dry powder
composition
acetylsalicylic acid
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177005617A
Other languages
English (en)
Korean (ko)
Other versions
KR20170039255A (ko
Inventor
캠비즈 야디디
Original Assignee
벡추라 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102603897(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 벡추라 인코포레이티드 filed Critical 벡추라 인코포레이티드
Priority to KR1020237026168A priority Critical patent/KR102666667B1/ko
Publication of KR20170039255A publication Critical patent/KR20170039255A/ko
Application granted granted Critical
Publication of KR102603897B1 publication Critical patent/KR102603897B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177005617A 2014-07-31 2015-07-31 흡입용 건조 분말 제형 Active KR102603897B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237026168A KR102666667B1 (ko) 2014-07-31 2015-07-31 흡입용 건조 분말 제형

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
US62/031,811 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026168A Division KR102666667B1 (ko) 2014-07-31 2015-07-31 흡입용 건조 분말 제형

Publications (2)

Publication Number Publication Date
KR20170039255A KR20170039255A (ko) 2017-04-10
KR102603897B1 true KR102603897B1 (ko) 2023-11-20

Family

ID=55218356

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177005617A Active KR102603897B1 (ko) 2014-07-31 2015-07-31 흡입용 건조 분말 제형
KR1020237026168A Active KR102666667B1 (ko) 2014-07-31 2015-07-31 흡입용 건조 분말 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237026168A Active KR102666667B1 (ko) 2014-07-31 2015-07-31 흡입용 건조 분말 제형

Country Status (10)

Country Link
EP (2) EP4218734A1 (enExample)
JP (1) JP6850524B2 (enExample)
KR (2) KR102603897B1 (enExample)
CN (2) CN116687887A (enExample)
AU (2) AU2015296142A1 (enExample)
CA (1) CA2991760C (enExample)
DK (1) DK3179986T3 (enExample)
ES (1) ES2942297T3 (enExample)
PL (1) PL3179986T3 (enExample)
WO (1) WO2016019253A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019059953A2 (en) * 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100258118A1 (en) * 2006-11-03 2010-10-14 Vectura Limited Inhaler devices and bespoke pharmaceutical compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
WO1996032096A1 (en) 1995-04-14 1996-10-17 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
EE04004B1 (et) 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JP2001517692A (ja) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1913939T (pt) * 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
PT1455755E (pt) 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
NZ561649A (en) 2005-03-28 2011-02-25 Pericor Therapeutics Inc Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
US8614255B2 (en) 2007-08-21 2013-12-24 Civitas Therapeutics, Inc. Pulmonary pharmaceutical formulations
WO2009103035A2 (en) 2008-02-13 2009-08-20 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
US20120160944A1 (en) 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
CN104703584B (zh) 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218855A1 (zh) * 2013-04-30 2017-03-17 Otitopic Inc. 干粉製劑及使用方法
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100258118A1 (en) * 2006-11-03 2010-10-14 Vectura Limited Inhaler devices and bespoke pharmaceutical compositions

Also Published As

Publication number Publication date
WO2016019253A1 (en) 2016-02-04
ES2942297T3 (es) 2023-05-31
EP4218734A1 (en) 2023-08-02
CN107072947A (zh) 2017-08-18
JP6850524B2 (ja) 2021-03-31
CN116687887A (zh) 2023-09-05
AU2020203437B2 (en) 2020-09-17
WO2016019253A9 (en) 2016-05-12
KR20170039255A (ko) 2017-04-10
EP3179986A4 (en) 2018-02-07
EP3179986B1 (en) 2023-03-15
AU2015296142A1 (en) 2017-02-23
AU2020203437A1 (en) 2020-06-11
CA2991760A1 (en) 2016-02-04
PL3179986T3 (pl) 2023-06-26
KR102666667B1 (ko) 2024-05-17
CA2991760C (en) 2025-05-06
DK3179986T3 (da) 2023-05-01
JP2017523189A (ja) 2017-08-17
EP3179986A1 (en) 2017-06-21
KR20230119032A (ko) 2023-08-14

Similar Documents

Publication Publication Date Title
EP3107548B1 (en) Dry powder formulations for inhalation
AU2020203437B2 (en) Dry powder formulations for inhalation
US12343425B2 (en) Dry powder formulations for inhalation
US12144820B2 (en) Dry powder formulations for inhalation
HK1240081A1 (en) Dry powder formulations for inhalation
HK1240081B (en) Dry powder formulations for inhalation
HK1232442A1 (en) Dry powder formulations for inhalation
HK1232442B (en) Dry powder formulations for inhalation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220529

Patent event code: PE09021S01D

AMND Amendment
PE0601 Decision on rejection of patent

Patent event date: 20230227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220529

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220929

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230817

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230731

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230227

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220929

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration